NCT05188430 (CHITOCHOL) is a NA clinical trial of Medical Device (Kaptufat®) in Hypercholesterolemia, sponsored by University of Bologna.

Who is sponsoring NCT05188430?

NCT05188430 is sponsored by University of Bologna.

What drugs are being tested in NCT05188430?

Interventions in NCT05188430: Medical Device (Kaptufat®), Placebo.

What condition does NCT05188430 study?

NCT05188430 studies Hypercholesterolemia, Overweight and Obesity.

Is NCT05188430 still recruiting?

NCT05188430 is currently status unknown. Last updated 12 January 2022.

Last reviewed 2022-01-12 · How we verify

NCT05188430: CHITOCHOL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metabolic Effect of an Innovative Chitosan Formulation

Status unknown NA Last updated 12 January 2022

What this trial tests

NA trial testing Medical Device (Kaptufat®) in Hypercholesterolemia in 60 participants. Status unknown.

Timeline

1 March 2022

Primary endpoint
3 September 2022

3 September 2022

Quick facts

Lead sponsor	University of Bologna
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 March 2022
Primary completion	3 September 2022
Estimated completion	3 September 2022
Sites	1 location across Italy

Drugs / interventions tested

Medical Device (Kaptufat®)
Placebo

Conditions studied

Hypercholesterolemia — all drugs for Hypercholesterolemia →
Overweight and Obesity — all drugs for Overweight and Obesity →

Sponsor

University of Bologna

Who can join

Adults 18 to 70, any sex, with Hypercholesterolemia or Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chitosan is a natural polysaccharide of β-1,4-linked glucosamine residues deriving from chitin, a dietary fiber primarily obtained from fungal cell walls and the exoskeletons of various crustaceans (e.g. crab, lobster, and shrimp) and whose cholesterol-lowering properties are due to the hydrophobic bonds it forms with cholesterol and other sterols, interfering with the emulsification process in the intestine. In addition to reducing low-density lipoprotein cholesterol (LDL-C) levels, several studies showed that chitosan administration may help reduce body weight. For this reason, its use might be particularly useful as a strategy to simultaneously control two different risk factors for the development of CVDs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hypercholesterolemia

Currently open trials in the same condition.

NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
NCT07295327 — Effect of Two Food Supplements on Lipid Profile in Patients With Mild Hypercholesterolemia · NA · recruiting
NCT06568601 — Pharmacogenomic Informed Statin Prescribing · NA · recruiting
NCT06423365 — A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication. · NA · active not recruiting

Other University of Bologna trials

Trials by the same sponsor.

NCT07431047 — Fast-Track Protocol for Endovascular Aneurysm Repair (EVAR) of Infrarenal Abdominal Aortic Aneurysms · not yet recruiting
NCT07295197 — Oral Indicators for ED Screening · recruiting
NCT07198789 — Randomized, Double-blind Crossover Trial Comparing Low-GI Functional vs. Standard Wholegrain Carbohydrates on Glycolipid · NA · not yet recruiting
NCT07127796 — Non-inferiority RCT on Fish Waste-Derived vs. Synthetic Vitamin D Supplementation in Healthy Adults With Suboptimal Vita · NA · not yet recruiting
NCT07041060 — Evaluation of the Efficacy and Safety of Eolo in Patients With NERD · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05188430 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Bologna
Last refreshed: 12 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05188430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing